**1. Introduction**

Prostate adenocarcinoma is the second most common diagnosed malignancy and the fifth leading cause of cancer death among men worldwide in 2020, with an estimated 1,414,259 new cases reported in men, along with 375,000 deaths [1]. The incidence and mortality rate of prostate cancer correlates with increasing age, with the average age at diagnosis being 66 years old [2]. The highest incidences of prostate cancer were in North America, Southern Africa, Northern and Western Europe, the Caribbean, and Australia/New Zealand; the lowest incidence rates were in Asia and North Africa.

In the United States between 2012 and 2017, the incidence rate of prostate cancer for all races combined was 104/100,000 persons; it was 97/100,000 for non-Hispanic whites, 173/100,000 for blacks, and 52/100,000 for Asian/Pacific Islanders. The mortality rate for all races combined was 19/100,000 persons; 18/100,000 for non-Hispanic whites, 38/100,000 for blacks, and 18/100,000 for Asian/Pacific Islanders.
